Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (161-170 of 539) with videos related to

Pageof 54
Sort By:
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 22, 2007
Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosisArnt V Kristen, Jolanta B Perz, Stefan O Schonland, et al.
Oncotarget|October 6, 2017
Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trialJonathan P GroΔ, Johanna Nattenmüller, Stefan Hemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaDavid S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalitiesChristos Sachpekidis, Jennifer Mosebach, Martin T Freitag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Quality of Online Information on Multiple Myeloma Available for LaypersonsHenrike Staemmler, Sandra Sauer, Emma Pauline Kreutzer, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2020
Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple MyelomaFelix Krummradt, Sandra Sauer, Petra Pavel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myelomaBrigitte Neuber, Isabelle Herth, Claudia Tolliver, et al.
Pageof 54

Showing results (161-170 of 539) with videos related to

Sort By:
Pageof 54
Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m<sup>2</sup> vs. twice-weekly 27 mg/m<sup>2</sup> carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 22, 2007
Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosisArnt V Kristen, Jolanta B Perz, Stefan O Schonland, et al.
Oncotarget|October 6, 2017
Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trialJonathan P GroΔ, Johanna Nattenmüller, Stefan Hemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaDavid S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalitiesChristos Sachpekidis, Jennifer Mosebach, Martin T Freitag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor loadKai Neben, Anna Jauch, Thomas Hielscher, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Quality of Online Information on Multiple Myeloma Available for LaypersonsHenrike Staemmler, Sandra Sauer, Emma Pauline Kreutzer, et al.
Cancer|April 12, 2013
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patientsLeopold Sellner, Christiane Heiss, Axel Benner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2020
Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple MyelomaFelix Krummradt, Sandra Sauer, Petra Pavel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myelomaBrigitte Neuber, Isabelle Herth, Claudia Tolliver, et al.
Pageof 54